Lancet oncol: Mortality and influence factors after infection with the new coronavirus in different cancer patients.

CoVID-19 prognostics are poor in cancer patients.
cancer is a heterogeneic disease, including a range of tumor subsypes.
study aims to investigate the risk of COVID-19 based on tumor subsepes and demographic characteristics of cancer patients in the UK.
compared adult cancer patients who were selected to the UK New Coronavirus Cancer Detection Program (UKCCMP) from March 18 to May 8, 2020 with non-COVID-19UK cancer control populations from the UK Office for National Statistics.
endpoints were the effects of primary tumor subtypes, age and sex on the prevalence of severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) and the rate of death during hospitalization.
1044 patients in the UKCCMP queue, 319 (30.6%) died, of which 295 (92.5%) died from COVID-19.
the total cause of death after infection with SARS-CoV-2 in cancer patients was significantly associated with older age, increasing from 0.10 in the 40-49 age group to 0.48 in the 80-year-old population.
patients with blood malignancies (leukemia, lymphoma, and myeloma) had a more severe COVID-19 course of disease than patients with solid organ tumors (advantage ratio of 1.57, 95% CI 1.15-2.15; p.lt;0.0043).
the death rate of leukemia patients increased significantly compared to the rest of the UKCCMP queue (2.25, 1.13-4.57; p=0.023).
after age and gender correction, the risk of death increased further in patients with blood malignancies who had recently undergone chemotherapy during COVID-19-related hospitalization (OR 2.09, 95% CI 1.09 - 4.08; p - 0.028).
susceptible to SARS-CoV-2 infection and COVID-19 estypes in cancer patients with different tumor types.
this study produced a personalized risk table for cancer patients based on age, sex, and tumor subsype.
the findings may help doctors explain the risks of COVID-19 when informing patients of the risks-benefits and provide evidence for national social segregation policies.
.